EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   1.11.1.27 | Carcinoma |
17085654 |
Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
1
2
3
2 |
| 1.11.1.27 | Esophageal Squamous Cell Carcinoma |
17085654 |
Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
1
2
3
2 |
| 1.11.1.27 | Hypersensitivity |
23201565 |
2-Cys peroxiredoxin of Plasmodium falciparum is involved in resistance to heat stress of the parasite. |
ongoing research
unassigned |
2
0 |
| 1.11.1.27 | Lymphoma, B-Cell |
25935550 |
High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index. |
causal interaction
diagnostic usage
unassigned |
3
3
0 |
| 1.11.1.27 | Lymphoma, Large B-Cell, Diffuse |
25935550 |
High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index. |
causal interaction
diagnostic usage
unassigned |
3
3
0 |
